Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Medicine. Moving toward transparency of clinical trials.

Zarin DA, Tse T.

Science. 2008 Mar 7;319(5868):1340-2. doi: 10.1126/science.1153632. No abstract available.

2.

Progress and deficiencies in the registration of clinical trials.

Wood AJ.

N Engl J Med. 2009 Feb 19;360(8):824-30. doi: 10.1056/NEJMsr0806582. No abstract available. Erratum in: N Engl J Med. 2011 Apr 7;364(14):1382.

3.

[Regulations concerning data transparency- a comparison between the USA and Europe].

Quack C.

Z Evid Fortbild Qual Gesundhwes. 2011;105(3):183-8. doi: 10.1016/j.zefq.2011.03.006. German.

PMID:
21530907
4.

Making all clinical trials available for review: any impact on clinical decisions?

Smith GH.

J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):7-8. No abstract available.

PMID:
15730109
5.

Closing a loophole in the FDA Amendments Act.

Turner EH.

Science. 2008 Oct 3;322(5898):44-6. doi: 10.1126/science.322.5898.44c. No abstract available.

PMID:
18832629
6.

Clinical trials registries: towards improved access to therapeutic data.

[No authors listed]

Prescrire Int. 2008 Dec;17(98):256-9.

PMID:
19425275
8.

Few studies reporting results at US government clinical trials site.

Kuehn BM.

JAMA. 2012 Feb 15;307(7):651-3. doi: 10.1001/jama.2012.127. No abstract available.

PMID:
22337663
9.

Congress responds to the IOM drug safety report--in full.

Psaty BM, Korn D.

JAMA. 2007 Nov 14;298(18):2185-7. No abstract available.

PMID:
18000202
10.

Making clinical data widely available.

Kaiser J.

Science. 2008 Oct 10;322(5899):217-8. doi: 10.1126/science.322.5899.217. No abstract available.

PMID:
18845745
11.

Transparency for clinical trials--the TEST Act.

Drazen JM.

N Engl J Med. 2012 Aug 30;367(9):863-4. doi: 10.1056/NEJMe1209433. No abstract available.

12.

Drug safety. Gaps in the safety net.

Couzin J.

Science. 2005 Jan 14;307(5707):196-8. No abstract available.

PMID:
15653480
14.

Postmarketing surveillance and reporting of adverse drug events.

Baer RK.

S D J Med. 2004 Jan;57(1):13-4. Review. No abstract available.

PMID:
14964975
15.

Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.

Shea LL, Hanson A, Guglielmetti TM, Levy K.

Food Drug Law J. 2007;62(3):445-72. No abstract available.

PMID:
17915388
16.

The old file-drawer problem.

Kennedy D.

Science. 2004 Jul 23;305(5683):451. No abstract available.

17.

Trial Reporting in ClinicalTrials.gov - The Final Rule.

Zarin DA, Tse T, Williams RJ, Carr S.

N Engl J Med. 2016 Nov 17;375(20):1998-2004. No abstract available.

18.

Public registration of clinical trials.

Steinbrook R.

N Engl J Med. 2004 Jul 22;351(4):315-7. No abstract available.

19.

Trial-results reporting and academic medical centers.

Zarin DA, Tse T, Ross JS.

N Engl J Med. 2015 Jun 11;372(24):2371-2. doi: 10.1056/NEJMc1505965. No abstract available.

20.

Clinical trial data as a public good.

Rodwin MA, Abramson JD.

JAMA. 2012 Sep 5;308(9):871-2. doi: 10.1001/jama.2012.9661. No abstract available.

PMID:
22948695
Items per page

Supplemental Content

Support Center